MetaCap

Boundless Bio (BOLD) vs Rani Therapeutics (RANI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Boundless Bio (BOLD) has outperformed Rani Therapeutics (RANI) over the past year, gaining 105.3% versus a loss of 68.6%. Rani Therapeutics is the larger company by market cap ($59.0 million vs $54.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLD+105.31%RANI-68.64%
+177%+48%-80%
Nov 21, 20251 yearNov 20, 2026
BOLD-83.72%RANI-83.57%
+141%+18%-104%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLD versus RANI key metrics
MetricBOLDRANI
Share price$2.32$0.5111
Market cap$54.78M$59.03M
1-day change-2.52%-11.97%
YTD return+93.33%-62.14%
1-year return+105.31%-68.64%
5-year return—-98.34%
EPS (TTM)$-2.46$-0.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.63M
Revenue growth (YoY)—+58.85%
Net income (latest FY)$-58.20M$-29.67M
Operating margin—-2345.99%
Net margin—-1817.09%
52-week high$3.16$1.69
52-week low$0.961$0.502
Distance from 52-week high-26.68%-69.76%
Analyst consensusnonestrong_buy
Avg. price target upside+72.41%+1308.73%
Average volume131.34K545.67K
Shares outstanding23.61M115.49M
Employees2869
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BOLD has outperformed RANI by 174.0 percentage points over the past year.

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Rani Therapeutics

RANI stock →

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

BOLD vs RANI FAQ

Which is bigger, Boundless Bio or Rani Therapeutics?

Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $54.78M for Boundless Bio (BOLD).

Which stock has performed better over the past year, BOLD or RANI?

BOLD returned +105.31% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.

Are Boundless Bio and Rani Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons